Prospekteringsbolaget Bluelake Mineral (Bluelake) har tagit flera viktiga steg sedan föregående anal...
Sprint Bioscience has Q2 sales of SEK 16.7m (17.9m in Q1 and SEK 0m in Q2 2023), and the cash balanc...
Carlsquare Equity Research bedömer att start av influensaprojektet och flytten av labbverksamhet til...
Product sales (+13% y-o-y) and new billings (+12%) with the strongest growth rates in 2 years Uncert...
Redeye concludes that Systemair’s Q1 numbers are quite in-line with what we anticipated.
ODI Pharma published on August 29th the company’s Q4-report for 2023/2024, which showed a continued ...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) är en modern spelkoncern beståe...
Redeye comments on Lytix’ second quarter report 2024.
Redeye comments on Scandion Oncology’s Q2 2024 report, shortly after the company announced that its ...
AcuCort AB (”AcuCort” eller ”Bolaget”) har presenterat en Q2-rapport där mycket kretsar kring den st...
CoinShares International (CS) redovisade en stark justerad EBITDA under Q2 24 på 26,6 miljoner pund ...
Redeye comments on Cantargia's Q2 report. CAN10 is progressing according to plan with proof-of-mecha...
Redeye comments on Verve Group’s Q2 2024 numbers, which align with preliminary figures.
STENOCARE A/S (“STENOCARE” or the “Company”) has executed on several strategically important milesto...
Supported by the latest troponin data generated from whole blood samples on the final commercial car...
Redeye expects the Integrum share to trade down considerably during the day.
Etteplan lowered its guidance as the market conditions have remained weak.
We cut '24e-'26e EBITDA by 17-9% Still expect meaningful share of hardware-related sales NTM EV/EBIT...
Limited estimate revisions after solid Q2 with several promising signs Base machine is working, scal...
